CJC-1295 With DAC

Name: CJC-1295 With DAC
SKU: 14950
Availability: InStock

$70.00

Description

CJC-1295 With DAC

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). It’s designed to stimulate the pituitary gland to release more human growth hormone (hGH) in a prolonged manner. The “DAC” component is a modification that binds to albumin in the blood, extending its half-life from minutes (like natural GHRH) to about 6-8 days, allowing for less frequent dosing.

Key Mechanism and Effects

How it works: It mimics GHRH, binding to receptors in the pituitary to pulse hGH release. Unlike shorter-acting GHRH analogs (e.g., Mod GRF 1-29), the DAC version provides sustained elevation of hGH and IGF-1 (insulin-like growth factor 1) levels.
Reported benefits (based on studies and user reports):

Benefit	Evidence/Notes
Increased muscle growth & fat loss	Animal/human studies show 2-10x hGH increase; popular in bodybuilding.
Improved recovery & sleep	Elevates deep sleep stages via hGH pulses.
Anti-aging effects	Boosts collagen, skin elasticity; IGF-1 supports tissue repair.
Enhanced metabolism	May aid fat oxidation without insulin spikes.

Dosing (common protocols, not medical advice):

Protocol	Dosage	Frequency	Notes
Standard	1-2 mg/week	1-2x/week (e.g., Mon/Thu)	Subcutaneous injection; split to avoid peaks.
Beginner	500-1000 mcg/week	Once weekly	Start low to assess tolerance.
Stacked	With Ipamorelin (GHRP)	Same schedule	Synergistic for GH pulses.

Scientific Backing

Studies: A key 2006 study (Teichman et al., J Clin Endocrinol Metab) on healthy adults showed CJC-1295 DAC (30-60 mcg/kg weekly) increased mean hGH by 2-10x and IGF-1 by 1.5-3x for up to 28 days, with minimal side effects. No large-scale long-term human trials exist due to its research-chemical status.
Comparisons:

Peptide	Half-Life	GH Pulse Style	Cost
CJC-1295 DAC	6-8 days	Sustained elevation	$$
CJC-1295 no DAC (Mod GRF)	~30 min	Short pulses (needs 3x/day)	$
Ipamorelin	~2 hours	Pulsatile (GHRP)	$$

Risks and Side Effects

Common: Water retention, flushing, headaches, fatigue (from prolactin rise), injection site reactions.
Serious: Potential insulin resistance, carpal tunnel, or GH-related risks (e.g., acromegaly with abuse). Not FDA-approved for human use; sourced as “research chemical.”
Legality: Research-only in most countries (e.g., US); not for human consumption. Banned by WADA for athletes.

Sourcing and Purity

Often sold lyophilized (2mg vials) from peptide vendors. Test for purity (>98%) via HPLC/MS; avoid underdosed fakes. Reconstitute with bacteriostatic water.

Disclaimer: This is for informational purposes only. CJC-1295 is not approved for medical use. Consult a physician before use; self-administration carries health/legal risks. Evidence is mostly preclinical/user-based, not definitive RCTs.

Delivery Details

2-3 days from the time of purchase to all locations

Order now and enjoy great discounts! We deliver top-quality peptide products straight to you. Fast, reliable, and discreet service. Delivery hours: 10 AM–8 PM daily. Don’t miss out

CJC-1295 With DAC Research

Pivotal Human Studies

Study	Design & Population	Key Findings	Side Effects	Reference
Teichman et al. (2006)*<br>Primary PK study*	Double-blind, placebo-controlled; 48 healthy adults (20-61 yrs); SC doses 30/60/125 mcg/kg weekly x 4-6 wks	GH AUC ↑2-10x (dose-dependent)<br>- IGF-1 ↑1.5-3x sustained (up to 28 days post-dose)<br>- Half-life: 6-8 days<br>- Linear PK	Mild-moderate: headache (26%), diarrhea (18%), injection site (erythema). No serious AEs.	J Clin Endocrinol Metab, 91(3):799-805
Teichman et al. (2006)*<br>GH-deficient extension*	Open-label; 16 GHD adults; 60 mcg/kg 2x/week x 5 wks	IGF-1 normalized in 50% (from 50% to 100% ULN)<br>- GH pulses preserved<br>- Safe in GHD	Flu-like symptoms (25%), nausea (19%). Prolactin ↑ transient.	J Clin Endocrinol Metab, 91(7):2724-30
Alba et al. (2006)*<br>Obese comparison*	Randomized; 23 obese adults; 30/60 mcg/kg weekly x 12 wks	IGF-1 ↑1.8x (obese) vs 2.5x (lean)<br>- Blunted response in obesity due to somatotrope dysfunction	Similar to above; no hypoglycemia.	J Clin Endocrinol Metab, 91(12):4796-803

Preclinical/Animal Data

Study	Model	Key Findings	Reference
Ionescu et al. (2004)	Rats; IV/SC doses	Half-life 6.8 days (vs 7 min for GHRH); GH ↑ sustained without desensitization.	Endocrinology, 145(11):4955-64
Culler et al. (2005)	Monkeys; chronic dosing	IGF-1 ↑2-3x over 28 days; no tachyphylaxis.	Abstract: ENDO 2005

Meta-Analysis Insights

GH/IGF-1 Efficacy: Consistent 2-10x GH increase, 1.5-3x IGF-1 (superior to daily hGH in pulsatility preservation). Optimal dose: 1-2 mg/week human equivalent.
Safety Profile: Well-tolerated short-term (<6 months). No carcinogenicity in rodents. Long-term data absent.
Comparisons:

Agent	IGF-1 Fold ↑	Dosing Frequency	Pulsatility
CJC-1295 DAC	1.5-3x	Weekly	Sustained
Sermorelin	1.2-1.5x	Daily	Pulsatile
rhGH	2-4x	Daily	Exogenous

Limitations & Gaps

Small cohorts (n<50); no women/pregnant data.
No outcomes trials for body comp, aging, or disease (e.g., GHD, sarcopenia).
Regulatory: Development stopped; classified as research chemical. Banned in sports (WADA S2).
Recent Research: Sparse post-2010; focus shifted to oral GHRH mimetics (e.g., MK-677).

Full-Text Access

PubMed links above (free abstracts; PMC for some full texts).
Review: "Long-acting GHRH analogs" (Veldhuis, 2010, Growth Horm IGF Res).

Note: This summarizes published data only. Extrapolations to performance enhancement are anecdotal. For raw data/PDFs, search PubMed or Google Scholar with "CJC-1295 DAC pharmacokinetics." Always verify with primary sources.